This observational, multicenter, retrospective/prospective study will evaluate the use of Avastin (bevacizumab) in clinical practice in patients with metastatic colorectal cancer. Patients having initiated first-line treatment with a fluoropyrimidine-based chemotherapy and Avastin will be followed for up to 15 months.
Study Type
OBSERVATIONAL
Enrollment
437
Proportion of patients with Avastin treatment discontinuation due to either disease progression or Avastin-related adverse events
Time frame: approximately 15 months
Proportion of patients with treatment discontinuation due to other causes
Time frame: approximately 15 months
Incidence of other causes for treatment discontinuation
Time frame: approximately 15 months
Second-line treatments initiated
Time frame: approximately 15 months
Progression-free survival (patients with treatment discontinuation due to disease progression or Avastin-related toxicity as compared to patients with treatment discontinuation due to other causes)
Time frame: approximately 15 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
L’Aquila, Abruzzo, Italy
Unnamed facility
Teramo, Abruzzo, Italy
Unnamed facility
Brindisi, Apulia, Italy
Unnamed facility
Castellana Grotte (BA), Apulia, Italy
Unnamed facility
Foggia, Apulia, Italy
Unnamed facility
Lecce, Apulia, Italy
Unnamed facility
San Giovanni Rotondo, Apulia, Italy
Unnamed facility
Rionero in Vulture, Basilicate, Italy
Unnamed facility
Cosenza, Calabria, Italy
Unnamed facility
Lamezia Terme (CZ), Calabria, Italy
...and 62 more locations